Please provide your email address to receive an email when new articles are posted on . On May 11, Icelandic-based drug developer Alvotech filed a lawsuit against AbbVie seeking to undo what it ...
A few days ago, I published an AbbVie (ABBV) article titled "AbbVie: The Humira Situation Remains Scary". In that article, I covered the main implications (for AbbVie) of Humira's impending (2023) ...
Alberta, Canada becomes the latest province to begin switching patients from originator adalimumab (Humira) to biosimilar versions as part of its Biosimilars Initiative. Alberta, Canada has expanded ...
Biologic medicines—drugs with complex molecules developed in living cells—have saved lives and improved the quality of life ...
About 1.5 million Americans suffer from rheumatoid arthritis, a chronic disease in which the immune system attacks healthy cells, typically around the joints, causing swelling and deformity. Generally ...
Enbrel (etanercept) is a prescription brand-name medication. It’s approved by the Food and Drug Administration (FDA) to treat the following conditions: For each of these conditions, Enbrel is ...
LONDON, March 15 (Reuters) - Abbott Laboratories' drug Humira and Enbrel, from Pfizer and Amgen , should be the first choices for treating patients with psoriatic arthritis, Britain's ...
Shares of the immunology juggernaut AbbVie (NYSE: ABBV) were down by 4% on sky-high volume as of 11 a.m. ET Thursday. That's equivalent to a $7 billion drop in market capitalization. What's spooking ...
(Reuters) - Amgen Inc's cheaper version of AbbVie's top-selling arthritis drug Humira is highly similar to the original and should be approved, an advisory panel to the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback